AKR1C3 inhibitor KV-37 exhibits antineoplastic effects and potentiates enzalutamide in combination therapy in prostate adenocarcinoma cells

Kshitij Verma, Nehal Gupta, Tianzhu Zang, Phumvadee Wangtrakluldee, Sanjay K. Srivastava, Trevor M. Penning, Paul C. Trippier

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Fingerprint Dive into the research topics of 'AKR1C3 inhibitor KV-37 exhibits antineoplastic effects and potentiates enzalutamide in combination therapy in prostate adenocarcinoma cells'. Together they form a unique fingerprint.

Medicine & Life Sciences